OneMedNext Advances on Q2 Numbers
OneMedNet Corporation (NASDAQ:ONMD) shares began Thursday in the green. The Minneapolis-based company, claiming to be a leader in AI-powered Real-World Data (RWD), announced its financial results for the second quarter ended June 30, 2025, including its significantly improved balance sheet.
Due to the combination of debt conversions, vendor repayments, and highly discounted debt settlements, total liabilities have been reduced from $19.7 million as of December 31, 2024, to $6.2 million as of June 30, 2025, a reduction of approximately $13.5 million.
Additional discounted debt settlements in July 2025 further reduced liabilities by $1.9 million, resulting in aggregate reductions in liabilities by approximately 80% since December 31, 2024.
The combination of discounted debt settlements and debt conversions resulted in other income of $5.0 million in the second quarter of 2025 which contributed to overall net income of $3.0 million for the second quarter and $1.1 million of net income through June 30, 2025.
The company also successfully completed $3.7 million in private placements of Company securities, including $1.2 million of this investment from insiders, providing capital to accelerate sales execution, expand the iRWD™ platform, and support customer acquisition and operations.
As of June 30, 2025, the Company maintained a strategic digital asset position of 15 Bitcoin with a value of $1.6 million.
ONMD shares captured five cents, or 10.4%, to start Thursday at 53 cents.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


